OCUL101
Asset
Bispecific trap molecule simultaneously binding and inhibiting VEGF-A and complement C5.
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Neovascular age-related macular degeneration
Phase 2, Not yet recruiting, NCT07520318, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors6
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.